Moderna (Contract Mfg)

Norwood, MA
mRNA
10 confirmed programs · 4 sponsors · Last scored 2026-03-15
68.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (10) ○ SEC Filings ○ Press

Quick Facts: Moderna (Contract Mfg)

Signal Score
68.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Norwood, MA
Modalities
mRNA
Active CGT Programs
10 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 10
Sponsors4
ModalitiesmRNA
10 active programs across 4 sponsors
Modalities: mRNA
8 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07221474 A Study of V940/Placebo + Pembrolizumab and Chemotherapy in... PHASE2 Recruiting
NCT06946225 ACTengine® IMA203 Combined With mRNA-4203 PHASE1 Recruiting
NCT06623422 A Study of Pembrolizumab (MK-3475) With or Without Intismeran... PHASE3 Recruiting
NCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and... PHASE2/PHASE3 Active Not Recruiting
NCT06307431 A Study of Adjuvant Intismeran Autogene (V940) and... PHASE2 Active Not Recruiting
NCT06305767 A Clinical Study of Intismeran Autogene (V940) Treatment and... PHASE1/PHASE2 Active Not Recruiting
NCT06077760 A Study of Intismeran Autogene (V940) Plus Pembrolizumab... PHASE3 Recruiting
NCT05533697 Study of mRNA-4359 Administered Alone and in Combination With... PHASE1/PHASE2 Recruiting
NCT04805125 Immunocompromised Swiss Cohorts Based Trial Platform PHASE3 Completed
NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination... PHASE1 Terminated
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Subsidiary of Moderna
SEC FilingsParent: Moderna
Publicly traded — financial transparency
Capacity 53.0
1 CGT manufacturing site: Norwood, MA
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Norwood, MA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Norwood, MA
Modalities: mRNA
Capacity assessment: 53.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →